Literature DB >> 31449289

Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis.

Daniel M Hartung1, Dennis Bourdette2.   

Abstract

Entities:  

Year:  2019        PMID： 31449289     DOI： 10.1001/jamaneurol.2019.2445

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  6 in total

1.  Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs.

Authors:  Daniel M Hartung; Kirbee A Johnston; Dennis N Bourdette; Randi Chen; Chien-Wen Tseng
Journal:  Neurol Clin Pract       Date:  2021-08

2.  Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program.

Authors:  Daniel M Hartung; Kirbee A Johnston; Jessina C McGregor; Dennis N Bourdette
Journal:  Neurol Clin Pract       Date:  2022-02

3.  Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population.

Authors:  Daniel M Hartung; Kirbee A Johnston; Jessina C McGregor; Dennis N Bourdette
Journal:  Int J MS Care       Date:  2022-04-14

4.  On the horizon-the value and promise of the global pipeline of Alzheimer's disease therapeutics.

Authors:  Michael A Cole; Guy R Seabrook
Journal:  Alzheimers Dement (N Y)       Date:  2020-05-12

Review 5.  Health economics of disease-modifying therapy for multiple sclerosis in the United States.

Authors:  Daniel M Hartung
Journal:  Ther Adv Neurol Disord       Date:  2021-02-17       Impact factor: 6.570

Review 6.  The Neuroimmunology of Multiple Sclerosis: Fictions and Facts.

Authors:  Andrew R Pachner
Journal:  Front Neurol       Date:  2022-02-07       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.